THE FIRST CELL-BASED mRNA THERAPEUTICS PLATFORM
Synthetic mRNA has reached its limits. Our cell-based mRNA design and manufacturing platform enables pure, low immunogenicity mRNA that unlocks a new era of design-based biology.
Sensible Biotechnologies Teams Up With NVIDIA to Develop Computational Engine for Cell-Based mRNA Therapeutics Design •
Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible’s Unique Cell-Based mRNA Design and Manufacturing Platform •
Sensible Biotechnologies Teams Up With NVIDIA to Develop Computational Engine for Cell-Based mRNA Therapeutics Design •
Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible’s Unique Cell-Based mRNA Design and Manufacturing Platform •
Synthetic mRNA has reached its limits. Our cell-based mRNA design and manufacturing platform enables pure, low immunogenicity mRNA that unlocks a new era of design-based biology.
